GLP-1 drugs are blockbuster medications for weight loss and Type 2 diabetes. Now doctors are trying them for lymphedema, swelling that can be caused by cancer treatment.

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

CompanyOverview|NYSE:HIMS] One of the more hotly debated stocks in the market, Hims & Hers Health (NYSE: HIMS), recently made ...

Senator John Fetterman, a democrat from Pennsylvania, admitted to using weight loss drug Mounjaro and issued a desperate plea ...

Such medications are just one part of a necessary, holistic approach that includes diet, exercise, and addressing significant ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Across Wall Street, 44 publicly traded companies were upgraded Tuesday to an equivalent rating of "buy" or "neutral." ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Dr. Daniel Drucker, an endocrinologist and a clinician-scientist at the University of Toronto and the Lunenfeld-Tanenbaum ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...